CLOBETASOL.(Taro Pharmaceuticals USA receives FDA approval)(Brief Article)

Chemical Market Reporter, May, 2000

Taro Pharmaceutical Industries Ltd.'s US subsidiary, Taro Pharmaceuticals USA Inc., has received Food and Drug Administration approval for its abbreviated new drug application for clobetasol propionate emollient cream USP, 0.05 percent. Taro has also received FDA approval for nortriptyline hydrochloride capsules USP, 10 mg, 25 mg, 50 mg and 75 mg.

The company was also issued a patent in Israel for its NonSpil drug delivery system.